Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) has seen a rise in its stock price by 2953932 in relation to its previous close of 16.95. However, the company has experienced a -0.62% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
Company’s 36-month beta value is 0.61.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TEVA is 1.15B, and currently, short sellers hold a 3.11% ratio of that floaft. The average trading volume of TEVA on June 23, 2025 was 12.25M shares.
TEVA’s Market Performance
TEVA’s stock has seen a -0.62% decrease for the week, with a 2.02% rise in the past month and a 4.88% gain in the past quarter. The volatility ratio for the week is 2.75%, and the volatility levels for the past 30 days are at 2.73% for Teva- Pharmaceutical Industries Ltd. ADR The simple moving average for the past 20 days is -2.70% for TEVA’s stock, with a -3.31% simple moving average for the past 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Goldman repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Goldman is $24 based on the research report published on June 06, 2025 of the current year 2025.
Truist, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $25. The rating they have provided for TEVA stocks is “Buy” according to the report published on May 28th, 2025.
JP Morgan gave a rating of “Overweight” to TEVA, setting the target price at $23 in the report published on May 12th of the current year.
TEVA Trading at 3.55% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.94% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Kalif Eliyahu Sharon, who sale 55,775 shares at the price of $17.08 back on Jun 12 ’25. After this action, Kalif Eliyahu Sharon now owns 403,288 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $952,464 using the latest closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.49 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.08. The total capital return value is set at 0.02. Equity return is now at value -18.98, with -3.17 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 2.71. The interest coverage ratio of the stock is 0.44.
Currently, EBITDA for the company is 716.0 million with net debt to EBITDA at 10.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.09. The receivables turnover for the company is 4.91for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
In a nutshell, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
